HRTX

Heron Therapeutics Inc

0.3250

Aug 25 • 7:23 AM ET +0.0022 (0.68%)

Healthcare Biotechnology USA Micro NASD

Peers: ARCT VYGR CDXS FENC OBIO RNAC SLGL BCYC FATE FHTX

| Held by: VTI IWM VXF VTWO IWO SCHA VHT IWC IWN VTWG

Index	RUT
Market Cap	61.70M
Enterprise Value	168.44M
Income	-34.05M
Sales	151.18M
Book/sh	0.03
Cash/sh	0.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	128
IPO	Aug 26, 1987

P/E	-
Forward P/E	-
PEG	-
P/S	0.41
P/B	10.51
P/C	1.45
P/FCF	-
EV/EBITDA	-
EV/Sales	1.11
Quick Ratio	1.51
Current Ratio	2.49
Debt/Eq	21.47
LT Debt/Eq	21.44
Option/Short	Yes / Yes

EPS (ttm)	-0.19
EPS next Y	-0.11
EPS next Q	-0.03
EPS this Y	-8.33%
EPS next Y	15.38%
EPS next 5Y	22.90%
EPS past 3/5Y	58.31% 45.44%
Sales past 3/5Y	12.89% 11.81%
EPS Y/Y TTM	-3014.75%
Sales Y/Y TTM	0.99%
EPS Q/Q	-85.81%
Sales Q/Q	1.25%
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-500.00% -10.72%

Insider Own	2.33%
Insider Trans	0.00%
Inst Own	69.27%
Inst Trans	-10.76%
ROA	-14.06%
ROE	-
ROIC	-21.96%
Gross Margin	70.07%
Oper. Margin	-6.99%
Profit Margin	-22.52%
SMA20	-17.58%
SMA50	-22.58%
SMA200	-64.54%
Trades

Shs Outstand	189.46M
Shs Float	185.43M
Short Float	23.32%
Short Ratio	12.20
Short Interest	43.24M
52W High	1.58 -79.37%
52W Low	0.30 9.24%
Volatility	7.41% 9.34%
ATR (14)	0.03
RSI (14)	32.92
Beta	1.63
Rel Volume	0.00
Avg Volume	3.54M
Volume	388

Perf Week	8.01%
Perf Month	-29.22%
Perf Quarter	-63.21%
Perf Half Y	-70.18%
Perf YTD	-75.00%
Perf Year	-76.45%
Perf 3Y	-80.54%
Perf 5Y	-97.21%
Perf 10Y	-98.31%
Recom	3.00
Target Price	0.34
Prev Close	0.32
Price	0.32
Change %	0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-03-26	Downgrade	Needham	Buy → Hold
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57

Show Previous Ratings

Aug-10-26 05:01PM	Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) -31.74%
11:05AM	Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook (InvestorsHub)
08:06AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press)
08:00AM	Heron Therapeutics Announces Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-27-26 08:30AM	Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 (GlobeNewswire)
11:04PM	Loading…
Jun-02-26 11:04PM	Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -45.60%
08:12AM	U.S. District Court Issues Decision Regarding CINVANTI Patents (GlobeNewswire)
May-12-26 03:02AM	Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges (GuruFocus.com)
May-11-26 04:51PM	Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby) -21.05%
11:03AM	Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline (InvestorsHub)
08:07AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press)
08:00AM	Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance (GlobeNewswire)
Apr-27-26 05:30PM	Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 (GlobeNewswire)
Feb-26-26 04:33PM	Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +11.11%
04:09PM	Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
03:48PM	Loading…
03:48PM	Heron Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:30PM	Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:19AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-17-26 08:30AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 (GlobeNewswire)
Jan-10-26 09:35AM	Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M (TipRanks)
Jan-09-26 09:29AM	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth (GlobeNewswire) +9.45%
Dec-04-25 08:15AM	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire)
Nov-04-25 04:06PM	Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:13AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress (GlobeNewswire)
Oct-29-25 05:58PM	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors (GlobeNewswire)
Oct-21-25 04:20PM	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire) -8.46%
07:45AM	Loading…
Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

CEO & DirectorMr. Craig Alexander Collard

Executive VP & CFOMs. Ira Duarte

Executive VP & COOMr. Mark E. Hensley

Pharm.D.Dr. William P. Forbes Pharm. D.

Vice President of LegalMelissa Jarel

HRTX

Heron Therapeutics Inc

Upgrade your Finviz experience